Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Senderowicz

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Leukemia|March 13, 2001
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignanciesA M Senderowicz
Oncogene|June 28, 2001
Small molecule modulators of cyclin-dependent kinases for cancer therapyA M Senderowicz
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapyA M Senderowicz
Investigational New Drugs|February 9, 2000
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trialsA M Senderowicz
Journal of the National Cancer Institute|March 4, 2000
Preclinical and clinical development of cyclin-dependent kinase modulatorsA M Senderowicz, E A Sausville
International Journal of Oncology|September 21, 2000
Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridolY Li, S R Chinni, A M Senderowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridolY Li, M Bhuiyan, S Alhasan, et al.
Annals of the New York Academy of Sciences|July 27, 2000
Inhibition of CDKs as a therapeutic modalityE A Sausville, J Johnson, M Alley, et al.
International Journal of Oncology|June 22, 1999
Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell lineH R Lee, T H Chang, M J Tebalt, et al.
Frontiers in Bioscience : a Journal and Virtual Library|April 3, 2001
Histone acetylation and the cell-cycle in cancerC Wang, M Fu, S Mani, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Leukemia|March 13, 2001
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignanciesA M Senderowicz
Oncogene|June 28, 2001
Small molecule modulators of cyclin-dependent kinases for cancer therapyA M Senderowicz
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapyA M Senderowicz
Investigational New Drugs|February 9, 2000
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trialsA M Senderowicz
Journal of the National Cancer Institute|March 4, 2000
Preclinical and clinical development of cyclin-dependent kinase modulatorsA M Senderowicz, E A Sausville
International Journal of Oncology|September 21, 2000
Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridolY Li, S R Chinni, A M Senderowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridolY Li, M Bhuiyan, S Alhasan, et al.
Annals of the New York Academy of Sciences|July 27, 2000
Inhibition of CDKs as a therapeutic modalityE A Sausville, J Johnson, M Alley, et al.
International Journal of Oncology|June 22, 1999
Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell lineH R Lee, T H Chang, M J Tebalt, et al.
Frontiers in Bioscience : a Journal and Virtual Library|April 3, 2001
Histone acetylation and the cell-cycle in cancerC Wang, M Fu, S Mani, et al.
Pageof 4